{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:07:24Z","timestamp":1777075644843,"version":"3.51.4"},"reference-count":24,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The best of the best 4.0"},{"name":"Operational Program Knowledge Education Development"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The knowledge concerning mild-to-moderate renal toxicity of adjuvant chemotherapy (CTH) in colon cancer patients is scarce. We retrospectively evaluated changes in the estimated glomerular filtration rate (eGFR) after three months of adjuvant treatment and the overall renal risk of the 6-month regimen in 145 patients who completed three months of therapy at three oncological centers. A decrease in eGFR of at least 1.5 mL\/min\/1.73 m2 after three months and 3.0 mL\/min\/1.73 m2 after six months was considered relevant in terms of kidney-related cardiovascular risk. Out of 114 patients who completed a 6-month regimen, kidney function deterioration occurred in 62 (54.4%) after 3 months and in 54 (47.4%) after 6 months. Age \u2265 70 years (RR = 2.66; 95% CI: 1.15\u20136.16) and diabetes (RR = 2.52; 95% CI: 0.98\u20136.45) were risk factors for kidney outcomes during the first three months of CTH. However, renal function decline during the first three months did not increase the risk of further deterioration on CTH continuation. In conclusion, older age and diabetes are factors increasing the risk of renal function deterioration during adjuvant CTH in colon cancer patients without preexisting chronic kidney disease. However, the decline during the first three months does not allow for predicting further changes under continued adjuvant therapy.<\/jats:p>","DOI":"10.3390\/curroncol32060351","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T06:19:28Z","timestamp":1749795568000},"page":"351","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Renal Function Deterioration in Postoperative (Adjuvant) Chemotherapy for Colon Cancer\u2014Real-Life Data"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5626-9960","authenticated-orcid":false,"given":"Aleksandra","family":"G\u0142ady\u015b","sequence":"first","affiliation":[{"name":"Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia in Katowice, 40-029 Katowice, Poland"},{"name":"Department of Oncology and Radiotherapy, Medical University of Silesia in Katowice, 40-514 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-5006","authenticated-orcid":false,"given":"Sylwia","family":"Kozak","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia in Katowice, 40-029 Katowice, Poland"},{"name":"Department of Oncology and Radiotherapy, Medical University of Silesia in Katowice, 40-514 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1179-6932","authenticated-orcid":false,"given":"Aleksander Jerzy","family":"Owczarek","sequence":"additional","affiliation":[{"name":"Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical University of Silesia in Katowice, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-9563","authenticated-orcid":false,"given":"Ewa","family":"Cedrych","sequence":"additional","affiliation":[{"name":"Department of Oncology, Katowice Oncology Center, 40-074 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-3596","authenticated-orcid":false,"given":"Zofia Irena","family":"Niemir","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Diseases, University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5827-8473","authenticated-orcid":false,"given":"Stanis\u0142aw","family":"\u0141\u0105cki-Zynzeling","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia in Katowice, 40-029 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-4602","authenticated-orcid":false,"given":"Anna","family":"Chudek","sequence":"additional","affiliation":[{"name":"Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical University of Silesia in Katowice, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0566-7650","authenticated-orcid":false,"given":"Izolda","family":"Mrochen-Domin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Katowice Oncology Center, 40-074 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6320-0224","authenticated-orcid":false,"given":"Iwona","family":"Gisterek-Grocholska","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Medical University of Silesia in Katowice, 40-514 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6367-7794","authenticated-orcid":false,"given":"Jerzy","family":"Chudek","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases and Oncological Chemotherapy, Medical University of Silesia in Katowice, 40-029 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"ref_1","unstructured":"(2024, December 08). Cancer.net. Available online: https:\/\/www.cancer.net\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Taieb, J., and Gallois, C. (2020). Adjuvant Chemotherapy for Stage III Colon Cancer. Cancers, 12.","DOI":"10.3390\/cancers12092679"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM199002083220602","article-title":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","volume":"322","author":"Moertel","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"(1995). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet, 345, 939\u2013944.","DOI":"10.1016\/S0140-6736(95)90696-7"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa010957","article-title":"A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients","volume":"345","author":"Sargent","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CCC.2006.n.046","article-title":"Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: Overview of efficacy, safety, and cost-effectiveness","volume":"6","author":"Twelves","year":"2006","journal-title":"Clin. Colorectal Cancer."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study","volume":"33","author":"Vernerey","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","article-title":"Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients","volume":"25","author":"Figer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11888-013-0181-6","article-title":"The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status","volume":"9","author":"Ohtsu","year":"2013","journal-title":"Curr. Colorectal Cancer Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1681\/ASN.2019030238","article-title":"CKD: A Call for an Age-Adapted Definition","volume":"30","author":"Indridason","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/MNH.0000000000000210","article-title":"Change in estimated glomerular filtration rate and outcomes in chronic kidney disease","volume":"25","author":"Ferguson","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_13","first-page":"1291","article-title":"ESMO Guidelines Committee. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"3","author":"Salazar","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhang, L., Li, Q., Hu, C., Zhang, Z., She, J., and Shi, F. (2023). Real-world analysis of survival benefit of surgery and adjuvant therapy in elderly patients with colorectal cancer. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-41713-1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jgo.2018.06.002","article-title":"Causes of mortality in older patients with stage 3 colon cancer","volume":"10","author":"Raycraft","year":"2019","journal-title":"J. Geriatr. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Rougier","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","article-title":"Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients","volume":"49","author":"Twelves","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0093-7754(03)00401-9","article-title":"Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute organ dysfunction working group","volume":"30","author":"Hamilton","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kozlowski, L., Bielawska, K., Zhymaila, A., and Malyszko, J. (2022). Chronic Kidney Disease Prevalence in Patients with Colorectal Cancer Undergoing Surgery. Diagnostics, 12.","DOI":"10.3390\/diagnostics12092137"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: An update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/DCR.0b013e3182600db7","article-title":"Impact of chronic kidney disease on outcomes of surgical resection for primary colorectal cancer: A retrospective cohort review","volume":"55","author":"Nozawa","year":"2012","journal-title":"Dis. Colon. Rectum."},{"key":"ref_23","unstructured":"(2025, June 09). Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Available online: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.annonc.2024.05.034","article-title":"23P Renal impairment evaluation on postoperative (adjuvant) chemotherapy for colon cancer","volume":"35","author":"Gladys","year":"2024","journal-title":"Ann. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/351\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:51:22Z","timestamp":1760032282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["curroncol32060351"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32060351","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}